Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically proven diagnosis of a malignant disease for which no
satisfactory treatment exists at the time of enrollment

- Patients with brain metastases which at the time of study enrollment are controlled
and do not require treatment with corticosteroids are eligible

PATIENT CHARACTERISTICS:

Inclusion criteria:

- WHO performance status 0-2

- Life expectancy ≥ 3 months

- ANC > 1.5 x 10^9/L

- Platelet count > 100 x 10^9/L

- Creatinine clearance > 50 mL/min

- Serum bilirubin < 1.5 mg/dL

- AST and ALT < 2.0 times upper limit of normal (unless clearly due to the presence of
tumor)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Patient must be capable of understanding the nature of the trial and must give
written informed consent

Exclusion criteria:

- Unstable or severe intercurrent medical conditions or active, uncontrolled infection

- History of allergic reactions to non-steroidal anti-inflammatory drugs (NSAIDs)

- History of bleeding peptic ulcer within the past 3 months

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

- Recovered from all prior chemotherapy or radiotherapy

- Concurrent aspirin for cardiovascular indications allowed

- More than 2 weeks since prior and no other concurrent NSAIDs

Exclusion criteria:

- Had radiotherapy or chemotherapy within 3 weeks (nitrosoureas or mitomycin C within 6
weeks) prior to anticipated first day of dosing

- Undergoing concurrent therapy with other investigational agents or antineoplastic
therapy